Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer.
Phase 1
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000004332
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigatior 3.Patient with severe underlying disease 4.Patient with severe allergy disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of safety Postoperative progression free survival Postoperative overall survival
- Secondary Outcome Measures
Name Time Method